What is cancer anorexia-cachexia syndrome? A historical perspective

被引:1
|
作者
Bennani-Baiti, N. [1 ]
Walsh, D. [2 ]
机构
[1] Cleveland Clin, Sect Palliat Med & Support Oncol, Taussig Canc Ctr, Cleveland, OH 44106 USA
[2] Cleveland Clin, Harry R Horvitz Ctr Palliat Med, Taussig Canc Ctr, Cleveland, OH 44106 USA
关键词
Anorexia; cachexia; cancer; definition; syndrome;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer anorexia-cachexia syndrome (CACS) is a lethal but poorly defined involuntary wasting disorder. Loss of skeletal muscle and fat distinguishes it from starvation. Cachexia has been described as a clinical syndrome since ancient times, and the poor prognosis has long been acknowledged. In this article we have reviewed historical perspectives on cancer cachexia, and commented on modern definitions. In cancer cachexia, most historical descriptions included anorexia, wasting and a pale complexion. Other associated symptoms, such as fatigue, early satiety and taste changes, were inconsistently described. Newer descriptions have not significantly expanded the clinical picture. Today, there is still no consensus definition, hindering research on early diagnosis and effective therapy. The language descriptors used to characterise the syndrome are important. For example, the word 'cachexia' itself may mislead; perhaps cancer-related wasting syndrome is more accurate. Cancer anorexia-cachexia syndrome is a disorder associated with high morbidity and mortality, and deserves greater attention in both clinical and translational research.
引用
收藏
页码:257 / 262
页数:6
相关论文
共 50 条
  • [31] Megestrol acetate for treatment of anorexia-cachexia syndrome
    Ruiz Garcia, Vicente
    Lopez-Briz, Eduardo
    Carbonell Sanchis, Rafael
    Gonzalvez Perales, Jose Luis
    Bort-Marti, Sylvia
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (03):
  • [32] Mediators involved in the cancer anorexia-cachexia syndrome:: past, present, and future
    Argilés, JM
    Busquets, S
    García-Martínez, C
    López-Soriano, FJ
    NUTRITION, 2005, 21 (09) : 977 - 985
  • [33] Anorexia-Cachexia Syndrome in Pancreatic Cancer: Recent Development in Research and Management
    Uomo, Generoso
    Gallucci, Fernando
    Rabitti, Pier Giorgio
    JOURNAL OF THE PANCREAS, 2006, 7 (02): : 157 - 162
  • [34] Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway
    Camps, Carlos
    Iranzo, Vega
    Bremnes, Roy M.
    Sirera, Rafael
    SUPPORTIVE CARE IN CANCER, 2006, 14 (12) : 1173 - 1183
  • [35] Assessing and managing the symptoms associated with the anorexia-cachexia syndrome in cancer patients
    Andrew, I.
    Holden, K.
    Hawkins
    PHARMACY WORLD & SCIENCE, 2007, 29 (03): : 288 - 289
  • [36] Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
    Yu Bai
    Yunxia Hu
    Yanhua Zhao
    Xizhong Yu
    Junwei Xu
    Zhiyun Hua
    Zhiqiang Zhao
    Supportive Care in Cancer, 2017, 25 : 1651 - 1659
  • [37] Primary tumorous anorexia-cachexia syndrome and forms of intervention
    Jarisch, N.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 737 - 737
  • [38] Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome
    Fujitsuka, Naoki
    Uezono, Yasuhito
    FRONTIERS IN PHARMACOLOGY, 2014, 5
  • [39] A New Horizon of Herbal Medicines in Anorexia-Cachexia Syndrome
    Inui, Akio
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (31) : 4747 - 4748
  • [40] Audit of symptoms and prescribing in patients with the anorexia-cachexia syndrome
    Andrew, Inga
    Kirkpatrick, Graeme
    Holden, Keith
    Hawkins, Colette
    PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 489 - 496